Loading organizations...
§ Private Profile · Tokyo, Tokyo, Japan
Drug discovery company developing small-molecule therapeutics using computational platforms for oncology, immunology, and rare diseases.
Alivexis is a preclinical-stage biopharmaceutical company based in Tokyo, Japan, with operations in Cambridge, Massachusetts, that develops small-molecule therapeutics using advanced computational chemistry and artificial intelligence. The enterprise focuses on rapidly identifying novel drug candidates for oncology, immunology, and rare diseases, currently advancing over 10 proprietary preclinical programs across its pipeline. Operating through equity rounds and collaborative research partnerships, the firm has raised approximately 6.66 billion JPY in total capital, including an initial 800 million JPY first closing of its Series D funding. The company generates revenue through out-licensing and strategic collaborations with major global industry players, securing backing and partnerships from recognizable entities such as Astellas Pharma, PeptiDream, JAFCO Group, and Fast Track Initiative. Originally established as Modulus Discovery in 2016, the organization was founded by S. Roy Kimura, Kazuki Ohno, and Taro Terauchi.
Alivexis has raised $52.8M across 3 funding rounds.
Alivexis has raised $52.8M in total across 3 funding rounds.
Alivexis has raised $52.8M across 3 funding rounds. Most recently, it raised $20.3M Series C in March 2022.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Mar 3, 2022 | $20.3M Series C | — | Green Co Invest Investment, Heights Capital Management, Jafco Ventures, Keio Innovation Initiative, Yusuke Matsumoto, Takahiro Mizumoto | Announced |
| May 13, 2020 | $25.3M Series B | — | DAI Ichi Life, Essential Pharma, Miwa Toyoda, Kotaro Yamagishi, Medifuture, Mizuho Capital, Mobile Internet Capital, Koki Hirota, SMBC Venture Capital, UTokyo Innovation Platform | Announced |
| Aug 9, 2018 | $7.2M Series A | — | Hisashi Mitsuguchi, Keiichi Masuya | Announced |
Alivexis has raised $52.8M in total across 3 funding rounds.
Alivexis's investors include Green Co-Invest Investment, Heights Capital Management, Jafco Ventures, Keio Innovation Initiative, Yusuke Matsumoto, Takahiro Mizumoto, Dai-ichi Life, Essential Pharma, Miwa Toyoda, Kotaro Yamagishi, Medifuture, Mizuho Capital.